Protagonist Therapeutics Inc stock PB Ratio (=12.88) is close to 10-year high of 12.9.
The historical rank and industry rank for Protagonist Therapeutics's PB Ratio or its related term are showing as below:
MEX:PTGX'
s PB Ratio Range Over the Past 10 Years
Min: 1.11 Med: 4.02 Max: 12.9
Current: 12.88
During the past 12 years, Protagonist Therapeutics's highest PB Ratio was 12.90. The lowest was 1.11. And the median was 4.02.
MEX:PTGX's PB Ratio is ranked worse than 89.2% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs MEX:PTGX: 12.88
During the past 12 months, Protagonist Therapeutics's average Book Value Per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 31.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.60% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Protagonist Therapeutics was 31.00% per year. The lowest was -17.50% per year. And the median was 8.90% per year.
Back to Basics: PB Ratio
Protagonist Therapeutics (MEX:PTGX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protagonist Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Protagonist Therapeutics (MEX:PTGX) has a PB Ratio of 8.51 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Protagonist Therapeutics and its competitors. This is 112% above median its historical median of 4.02. Over the past decade, Protagonist Therapeutics' PB Ratio has ranged from 1.11 to 12.90. According to the industry distribution chart, Protagonist Therapeutics ranks #1098 out of 1231 companies in the Biotechnology industry, placing it in the top 89.2%.
Is Protagonist Therapeutics' PB Ratio too high?
Protagonist Therapeutics' current PB Ratio of 8.51 is 112% above median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 12.90. The Biotechnology industry median PB Ratio is 2.93. Protagonist Therapeutics' value of 8.51 is 190.4% above this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #1098 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' PB Ratio compare to IMVT and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #1098 out of 1231 companies for PB Ratio. This places Protagonist Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.93. Protagonist Therapeutics' value of 8.51 is 190.4% above this benchmark. Historically, Protagonist Therapeutics' own PB Ratio has ranged from 1.11 to 12.90 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 2.93, Protagonist Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current PB Ratio of 8.51 is 190.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Protagonist Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current PB Ratio is 8.51, which is 112% above median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current PB Ratio of 8.51. The stock's GF Value™ is MXN751.22, compared to a current price of MXN1,565.33 — trading 108.4% above its estimated fair value. The current PB Ratio is 8.51, which is 112% above median its 10-year median of 4.02 and 190.4% above the Biotechnology industry median of 2.93. Protagonist Therapeutics' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current PB Ratio is 8.51 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of MXN1,565.33 is trading 108.4% above its estimated GF Value™ of MXN751.22.
Key valuation signals for MEX:PTGX:
PB Ratio: 8.51 (112% above median its 10-year median of 4.02)
GF Value™: MXN751.22 vs. price of MXN1,565.33 (108.4% above fair value)
Industry Position: 190.4% above the Biotechnology median (#1098 of 1231)
No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score
Get the complete analysis for MEX:PTGX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PTGX has been successfully added to your 
